- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Shore on a Long-Term Safety Analysis of the COU-AA-302 Study
May 23rd 2014, 10:36am
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.
Dr. Kapoor Discusses the Inclusion of Radium-223 in AUA Guidelines for CRPC
May 21st 2014, 8:27am
Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).
PSA Growth Rate May Help Identify Aggressive Prostate Cancer Early
May 21st 2014, 6:33am
Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.
Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study
May 20th 2014, 11:14am
Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.
Intermittent Degarelix Effective With Less Metabolic Syndrome Than Hormone Agonists, Studies Suggest
May 20th 2014, 10:15am
Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule
Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC
May 20th 2014, 8:20am
A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.
Dr. Crawford on Intermittent Androgen Deprivation With Degarelix
May 20th 2014, 6:26am
E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.
ED Therapy May Preserve Function, Penile Length After Prostatectomy
May 19th 2014, 12:16pm
Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.
Testicular Self-Examination Cost-Effective Compared with Missed Advanced Cancer
May 19th 2014, 6:01am
Testicular self-examination remains highly cost-effective despite a negative recommendation from the United States Preventive Services Task Force (USPSTF), a cost-utility analysis suggested.
In Dog Study, Prostate Cancer Found With a Whiff and a Woof
May 19th 2014, 5:31am
When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.
Dr. Aberger Discusses a Cost Analysis of Testicular Self-Examinations
May 18th 2014, 11:31am
Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.
Social Media Vital in Marketing Large Urology Practices
May 18th 2014, 7:57am
In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.
Physical Activity Linked to Lower Risk of Death from Bladder Cancer
May 18th 2014, 7:19am
Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.
Active Surveillance Is No Threat to Prostate Cancer Cure-So Far
May 18th 2014, 6:32am
Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.
Dr. Mirza on Hematuria and a Bladder Cancer Diagnosis
May 17th 2014, 9:24am
Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.
Dr. Rhee Discusses Workplace Violence in Urology Practices
May 17th 2014, 7:48am
Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.
As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes
May 14th 2014, 1:10pm
In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).
Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS
May 14th 2014, 1:05pm
The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.
For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality
May 14th 2014, 1:00pm
Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.
Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests
May 14th 2014, 1:00pm
A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.